Prf Technologies Ltd. · NASDAQ:PRFX
Prf Technologies — PainReform — Investor Presentation (July 2021)
16 slides from Prf Technologies's investor presentation, July 2021
Slide 1: Investor Presentation
Investor Presentation July 2021
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements about our expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward- looking words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”,
Slide 3: Management Team
Management Team Ehud Geller, PhD, MBA. Executive Chairman Former President & CEO of Interpharm Laboratories and EVP of Teva Group Former head of the Israeli Pharmaceutical Manufacturers Association and board member of the Tel Aviv Stock Exchange National Industry award for contribution to biot
Slide 4: PRF-110 Executive Summary
PRF-110 Executive Summary Post-operative pain treatment is a growing market (~$12B) with a need for better therapeutics1 o Local anesthetics provide pain relief for up to 6 hours and require augmentation with non-steroidal anti-inflammatory drugs (NSAIDs) o NSAIDs or opioids for moderate to severe
Slide 5: Post-Operative Pain Management Market Overview
Post-Operative Pain Management Market Overview The 2017 North America post-operative pain treatment market was estimated at ~$12B and is expected to reach ~$16B and $45B world-wide by the end of 20261 4 Significant unmet need for long-acting local anesthetic agents in order to spare opioids use,
Slide 6: Problem: State of Opioid Crisis in America
Problem: State of Opioid Crisis in America 99% of surgical patients receive opioids to manage post-surgical pain1 Opioids dependency can start within 3 days of initial use 11.4 Million 2.1 Million People misused opioids in 2019. 886K People have an opioid use disorder. 1.7 6% to 10% of surgica
Slide 7: Current Approaches in Post-Operative Analgesia Are Lacking
Current Approaches in Post-Operative Analgesia Are Lacking Short-Acting Opioids Long-Acting Opioids Repeated dosing required Poor efficacy in acute pain control Inconsistent pain control between doses Not intended for the treatment of post-operative pain Dependence risk increases with trea
Slide 8: PainReform Solution: PRF-110 Post Operative Pain Management
PainReform Solution: PRF-110 Post Operative Pain Management PainReform has developed a platform formulation for extended release of drugs Low COGS compared to current drug landscape Pain Reduction Time Scalable and Cost Effective Studies have shown 48 hours of pain Low variable costs allows for
Slide 9: PRF-110: Timeline to NDA
PRF-110: Timeline to NDA Historical Future FDA determined the CMC data Positive Phase 2, proof- adequate to of-concept study in Successful PRF- Study readouts ~9 proceed to Phase I hernia repair: pain 110 production in months after dosing first study control up to 72 hours the U.S. patient FDA agree
Slide 10: Product differentiation PRF-110 vs. Competition
Product differentiation PRF-110 vs. Competition Pacira1 – Exparel™ Heron2 - Zynrelef PRF-110 PRF-110 Advantages Watery, complex liposomal Biochronomer technology: Non-dilutable (Limited Waterless, viscous, oil- Formulation Uniformity, viscosity, & retention suspension market) based solution (GRAS) P
Slide 11: PRF-110 Safety
PRF-110 Safety PainReform carried out extensive FDA requested wound healing and related animal studies that showed: PRF-110 allows for normal wound healing of surgical incisions equal to both Naropin® and saline without any untoward histological or radiologic (microCT) effects observed in soft o
Slide 12: PRF-110 Phase 2 Results in Hernia
PRF-110 Phase 2 Results in Hernia PRF-110 Pain Reduction Up to 72-Hours After a Single Application 8 Efficacy PBO PRF-110 provided post- 7 Historical operative pain control for up placebo data 6 Mean Pain Score to 72 hours after a single PRF-110 Scale 1-10 application 5 4 Safety PRF-110 was
Slide 13: PRF-110: Phase III Clinical Trial Protocol
PRF-110: Phase III Clinical Trial Protocol Two, double blind, placebo control 72-hour treatment period, studies planned (bunionectomy and hernia surgery). For each study: Three cohorts (n= ~400): PRF-110; Naropin® (ropivacaine); placebo; in a 2:2:1 ratio Primary endpoint (Efficacy) • Compare the
Slide 14: PRF-110: Potential Best-In-Class
PRF-110: Potential Best-In-Class Efficacy Safety Cross study comparison of Phase II Met FDA required extensive pre-clinical studies data, 72 hours pain AUC to demonstrate no wound healing issues Administration COGS Low cost of good sold allows a highly PRF-110 viscosity and uniformity are highly str
Slide 15: Summary
Summary 1 2 3 4 5 Innovative Opioid Epidemic Seasoned Robust US and Core platform Formulation / Presents Management International can be utilized Delivery System Significant Team with IP Portfolio for wide-range Commercial Decades of of APIs to Opportunity Experience generate sustainable pipeline La
Slide 16: Thank You
Thank You